Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems

References

• Chen LH, Hedegaard H, Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief. 2014;166:1–8.
   PubMedGoogle Scholar
• Chen L-H, Hedegaard H, Warner M. QuickStats: number of deaths from poisoning, drug poisoning, and drug poisoning involving opioid analgesics—United States, 1999–2010. MMWR Morb Mortal Wkly Rept. 2010;62:234.
   Google Scholar
• Chen L-H, Hedegaard H, Warner M. QuickStats: rates of deaths from drug poisoning and drug poisoning involving opioid analgesics—United States, 1999–2013. MMWR Morb Mortal Wkly Rept. 2015;64:32.
   Web of Science ®Google Scholar
• Warner M, Hedegaard H, Chen L-H Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999–2012. 2014 [cited 2016 May 25]. Available from: http://www.cdc.gov/nchs/data/hestat/drug_poisoning/drug_poisoning.htm
   Google Scholar
• Paulozzi LJ, Jones CM, Mack KA, et al. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rept. 2011;60:1487–1492.
   PubMedGoogle Scholar
• Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–163.
   PubMed Web of Science ®Google Scholar
• Rudd RA, Aleshire N, Zibbell JE, et al. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rept. 2016;64:1378–1382.
   PubMed Web of Science ®Google Scholar
• Visconti AJ, Santos G-M, Lemos NP, et al. Opioid overdose deaths in the city and county of San Francisco: prevalence, distribution, and disparities. J Urban Health. 2015;92:758–772.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Specific drugs involved in drug poisoning deaths, 2008-2013. [cited 2016 May 25]. Available from: http://www.cdc.gov/nchs/pressroom/heroin_deaths.pdf
   Google Scholar
• Yokell MA, Delgado MK, Zaller ND, et al. Presentation of prescription and nonprescription opioid overdoses to US emergency departments. JAMA Intern Med. 2014;174:2034–2037.
   PubMed Web of Science ®Google Scholar
• Bailey JE, Campagna E, Dart RC, et al. The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med. 2009;53:419–424.
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Schiller M, et al. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009;15:897–906.
   PubMed Web of Science ®Google Scholar
• Whiteside LK, Walton MA, Bohnert ASB, et al. Nonmedical prescription opioid and sedative use among adolescents in the emergency department. Pediatrics. 2013;132:825–832.
   PubMed Web of Science ®Google Scholar
• Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med. 2014;15:1911–1929.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Grand Rounds: prescription drug overdoses- a U.S. epidemic. MMWR Morb Mortal Wkly Rept. 2012;61:10–13.
   PubMedGoogle Scholar
• Office of National Drug Control Policy. National Drug Control Strategy. 2014 [cited 2016 May 25]. Available from: https://www.whitehouse.gov/sites/default/files/ndcs_2014.pdf
   Google Scholar
• Frank D, Mateu-Gelabert P, Guarino H, et al. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy. 2015;26:84–91.
   PubMed Web of Science ®Google Scholar
• Boom M, Niesters M, Sarton E, et al. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des. 2012;18:5994–6004.
   PubMed Web of Science ®Google Scholar
• Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226–238.
   PubMed Web of Science ®Google Scholar
• Dahan A, Overdyk F, Smith T, et al. Pharmacovigilance: a review of opioid-induced respiratory depression in chronic pain patients. Pain Physician. 2013;16:E85–E94.
   PubMed Web of Science ®Google Scholar
• Niesters M, Overdyk F, Smith T, et al. Opioid-induced respiratory depression in paediatrics: a review of case reports. Br J Anaesth. 2013;110:175–182.
   PubMed Web of Science ®Google Scholar
• Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–1321.
   PubMed Web of Science ®Google Scholar
• Bond GR, Woodward RW, Ho M. The growing impact of pediatric pharmaceutical poisoning. J Pediatr. 2012;160:265–270.e1.
   Web of Science ®Google Scholar
• Burrows DL, Hagardorn AN, Harlan GC, et al. A fatal drug interaction between oxycodone and clonazepam. J Forensic Sci. 2003;48:683–686.
   PubMed Web of Science ®Google Scholar
• Coffey RJ, Owens ML, Broste SK, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111:881–891.
   PubMed Web of Science ®Google Scholar
• Darke S, Williamson A, Ross J, et al. Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. J Urban Health. 2007;84:283–291.
   PubMed Web of Science ®Google Scholar
• Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152:85–92.
   PubMed Web of Science ®Google Scholar
• Green TC, Grau LE, Carver HW, et al. Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007. Drug Alcohol Depend. 2011;115:221–228.
   PubMed Web of Science ®Google Scholar
• Havens JR, Oser CB, Knudsen HK, et al. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend. 2011;115:107–112.
   PubMed Web of Science ®Google Scholar
• Madadi P, Hildebrandt D, Lauwers AE, et al. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One. 2013;8:e60600.
   PubMed Web of Science ®Google Scholar
• Man L-H, Best D, Gossop M, et al. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. Eur Addict Res. 2004;10:35–40.
   PubMed Web of Science ®Google Scholar
• Neale J. Methadone, methadone treatment and non-fatal overdose. Drug Alcohol Depend. 2000;58:117–124.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Logan JE, Hall AJ, et al. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction. 2009;104:1541–1548.
   PubMed Web of Science ®Google Scholar
• Ruan X, Couch JP, Liu H, et al. Respiratory failure following delayed intrathecal morphine pump refill: a valuable, but costly lesson. Pain Physician. 2010;13:337–341.
   PubMed Web of Science ®Google Scholar
• Silva K, Schrager SM, Kecojevic A, et al. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. Drug Alcohol Depend. 2013;128:104–110.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Opioid overdose prevention toolkit. [updated 2016; cited 2016 May 25]. Available from: http://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit-Updated-2016/SMA16-4742.
   Google Scholar
• Warner-Smith M, Darke S, Lynskey M, et al. Heroin overdose: causes and consequences. Addiction. 2001;96:1113–1125.
   PubMed Web of Science ®Google Scholar
• Zedler B, Xie L, Wang L, et al. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans’ Health Administration patients. Pain Med. 2015;16:1566–1579.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Brown DFM, Tsugawa Y, et al. Epidemiology of emergency department visits for opioid overdose: a population-based study. Mayo Clin Proc. 2014;89:462–471.
   PubMed Web of Science ®Google Scholar
• Brain Injury Association of America. [cited 2016 May 25]. Available from: http://www.biausa.org/index.htm
   Google Scholar
• Caplan LR, Hurst JW, Chimowitz MI. Cardiac arrest and other hypoxic-ischemic insults. Clinical neurocardiology. New York (NY): CRC Press; 1999.
   Google Scholar
• National Emergency Medical Services for Children Data Analysis Resource Center. [cited 2016 May 25]. Available from: http://www.nedarc.org/emsDataSystems/nemsisReports/2010_11EMSTimes.html/
   Google Scholar
• Straus MM, Ghitza UE, Tai B. Preventing deaths from rising opioid overdose in the US - the promise of naloxone antidote in community-based naloxone take-home programs. Subst Abuse Rehabil. 2013;4:65–72.
   Google Scholar
• Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14(7):1137–1146.
   PubMed Web of Science ®Google Scholar
• Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29:265–271.
   PubMed Web of Science ®Google Scholar
• Edwards E, Kelley G, Kessler C, et al. Pharmacokinetics of 2.0 mg intranasal and intramuscular naloxone HCl administration and the impact of vasoconstrictor use on the bioavailability of intranasal naloxone HCl. Palm Springs (CA): American Academy of Pain Medicine; 2016.
   Google Scholar
• Harm Reduction Coalition. Understanding naloxone. [cited 2016 May 25]. Available from: http://harmreduction.org/issues/overdose-prevention/overview/overdose-basics/understanding-naloxone/
   Google Scholar
• National Institutes of Health. NARCAN- naloxone hydrochloride spray. [cited 2016 May 25]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=724df050-5332-4d0a-9a5f-17bf08a547e1
   Google Scholar
• National Institutes of Health. EVZIO- naloxone hydrochloride injection, solution. [cited 2016 May 25]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df501ed0-c0f4-11e3-8a33-0800200c9a66
   Google Scholar
• Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm. 2014;71:2129–2135.
   PubMed Web of Science ®Google Scholar
• Strang J, McDonald R, Tas B, et al. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? Addiction. 2016;111:574–582.
   PubMed Web of Science ®Google Scholar
• Wheeler E, Jones TS, Gilbert MK, et al. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rept. 2015;64:631–635.
   PubMed Web of Science ®Google Scholar
• Edwards ET, Edwards ES, Davis E, et al. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther. 2015;4:89–105.
   PubMed Web of Science ®Google Scholar
• Albert S, Brason FW 2nd, Sanford CK, et al. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011;12(suppl 2):S77–S85.
   PubMed Web of Science ®Google Scholar
• Brason FW 2nd, Roe C, Dasgupta N. Project Lazarus: an innovative community response to prescription drug overdose. N C Med J. 2013;74:259–261.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. MMWR Morb Mortal Wkly Rept. 2012;61:101–105.
   PubMedGoogle Scholar
• Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:297.
   PubMed Web of Science ®Google Scholar
• American Medical Association. Statement of the American Medical Association to the Committee on Energy & Commerce Subcommittee on Oversight and Investigations United States House of Representatives re: “combatting the opioid abuse epidemic: professional and academic perspectives”. [cited 2016 May 25]. Available from: http://docs.house.gov/meetings/IF/IF02/20150423/103367/HHRG-114-IF02-Wstate-HarrisP-20150423.pdf
   Google Scholar
• Compton WM, Volkow ND, Throckmorton DC, et al. Expanded access to opioid overdose intervention: research, practice, and policy needs. Ann Intern Med. 2013;158:65–66.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Management of substance abuse: community management of opioid overdose. [cited 2016 May 25]. Available from: http://www.who.int/substance_abuse/publications/management_opioid_overdose/en/
   Google Scholar
• American Society of Addiction Medicine. National practice guideline for the use of medications in the treatment of addiction involving opioid use. [cited 2016 May 25]. Available from: http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/asam-national-practice-guideline-supplement.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. [cited 2016 May 25]. Available from: http://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf
   Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Morb Mortal Wkly Rept. 2016;65:1–49.
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171:686–691.
   PubMed Web of Science ®Google Scholar
• Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613–624.
   PubMed Web of Science ®Google Scholar
• Deer TR, Leong MS, Buvanendran A, et al. Comprehensive treatment of chronic pain by medical, interventional, and integrative approaches. New York (NY): Springer Verlag; 2013.
   Google Scholar
• van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105:51–57.
   PubMed Web of Science ®Google Scholar
• Yassen A, Olofsen E, van Dorp E, et al. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. Clin Pharmacokinet. 2007;46:965–980.
   PubMed Web of Science ®Google Scholar
• Royal MA, Wiesemeyer DL, Gordin V. Intrathecal opioid conversions: the importance of lipophilicity. Neuromodulation. 1998;1:195–197.
   PubMed Web of Science ®Google Scholar
• Biedrzycki OJ, Bevan D, Lucas S. Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/beta-thalassemia and acute chest syndrome: a case report and review of the literature. Am J Forensic Med Pathol. 2009;30:188–190.
   PubMed Web of Science ®Google Scholar
• Knopf A. CDC report shows heroin and illicit fentanyl overdoses increasing. Alcoholism and Drug Abuse Weekly. 2016;28:1–3.
   Google Scholar
• Zuckerman M, Weisberg SN, Boyer EW. Pitfalls of intranasal naloxone. Prehosp Emerg Care. 2014;18:550–554.
   PubMed Web of Science ®Google Scholar
• Inturrisi CE, Max MB, Foley KM, et al. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med. 1984;310:1213–1217.
   PubMed Web of Science ®Google Scholar
• Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989;70:928–934.
   PubMed Web of Science ®Google Scholar
• Richarz U, Jacobs A, Spina E. How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain? Pharmacoepidemiol Drug Saf. 2012;21:453–462.
   PubMed Web of Science ®Google Scholar
• Fudin J, Fontenelle DV, Fudin HR, et al. Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone. J Pain Palliat Care Pharmacother. 2013;27:261–267.
   PubMedGoogle Scholar
• Bruehl S, Apkarian AV, Ballantyne JC, et al. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain. 2013;14:103–113.
   PubMed Web of Science ®Google Scholar
• Dowling J, Isbister GK, Kirkpatrick CMJ, et al. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit. 2008;30:490–496.
   PubMed Web of Science ®Google Scholar
• Edwards E, Gunn R, Kelley G, et al. Naloxone 0.4 mg bioavailability following a single injection with a novel naloxone auto-injector, EVZIO™ in healthy adults, with reference to a 1 mL standard syringe and intramuscular needle. Washington (DC): American Academy of Pain Medicine; 2015.
   Google Scholar
• Chan VO, Colville J, Persaud T, et al. Intramuscular injections into the buttocks: are they truly intramuscular? Eur J Radiol. 2006;58:480–484.
   PubMed Web of Science ®Google Scholar
• Cockshott WP, Thompson GT, Howlett LJ, et al. Intramuscular or intralipomatous injections? N Engl J Med. 1982;307:356–358.
   PubMed Web of Science ®Google Scholar
• Meltzer SJ, Auer J. On the rate of absorption from intramuscular tissue. J Exp Med. 1905;7:59–78.
   PubMedGoogle Scholar
• Geolot DH, McKinney NP. Administering parenteral drugs. Am J Nurs. 1975;75:788–793.
   PubMedGoogle Scholar
• Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108:871–873.
   PubMed Web of Science ®Google Scholar
• Beyea SC, Nicoll LH. Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure. Appl Nurs Res. 1995;8:23–33.
   PubMed Web of Science ®Google Scholar
• Evans EF, Proctor JD, Fratkin MJ, et al. Blood flow in muscle groups and drug absorption. Clin Pharmacol Ther. 1975;17:44–47.
   PubMed Web of Science ®Google Scholar
• Hess L, Malek J, Kurzova A, et al. The effect of site of intramuscular administration of anaesthetic drugs on the course of immobilisation in macaque monkeys (macaca mulatta): deltoid versus gluteus muscle. Eur J Anaesthesiol. 2011;28:146.
   PubMed Web of Science ®Google Scholar
• Zener JC, Kerber RE, Spivack AP, et al. Blood lidocaine levels and kinetics following high-dose intramuscular administration. Circulation. 1973;47:984–988.
   PubMed Web of Science ®Google Scholar
• Edwards ES, Edwards ET, Simons FE, et al. Drug-device combination products in the twenty-first century: epinephrine auto-injector development using human factors engineering. Expert Opin Drug Deliv. 2015;12:751–762.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Summary review for regulatory action: Evzio. 2014 [cited 2016 May 25]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205787Orig1s000SumR.pdf
   Google Scholar
• Center for Drug Evaluation and Research. Summary review for regulatory action: Narcan. 2015 [cited 2016 May 25]. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM480092.pdf
   Google Scholar
• Leiss JK. Management practices and risk of occupational blood exposure in U.S. paramedics: non-intact skin exposure. Ann Epidemiol. 2009;19:884–890.
   PubMed Web of Science ®Google Scholar
• Leiss JK, Ratcliffe JM, Lyden JT, et al. Blood exposure among paramedics: incidence rates from the national study to prevent blood exposure in paramedics. Ann Epidemiol. 2006;16:720–725.
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today. 2002;7:967–975.
   PubMed Web of Science ®Google Scholar
• Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
   PubMed Web of Science ®Google Scholar
• Barton ED, Ramos J, Colwell C, et al. Intranasal administration of naloxone by paramedics. Prehosp Emerg Care. 2002;6:54–58.
   PubMedGoogle Scholar
• Kelly A-M, Kerr D, Dietze P, et al. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182:24–27.
   PubMed Web of Science ®Google Scholar
• Kerr D, Kelly A-M, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104:2067–2074.
   PubMed Web of Science ®Google Scholar
• Wanger K, Brough L, Macmillan I, et al. Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med. 1998;5:293–299.
   PubMed Web of Science ®Google Scholar
• Edwards ET, Edwards ES, Kelley G, et al. Comparative simulated use study of a novel auto-injector and nasal delivery device for naloxone administration. Las Vegas (NV): PAINWeek; 2016.
   Google Scholar